Valuation : Cyclopharm Limited

Market Cap 64.75M 46.36M 40.02M 37.49M 34.23M 64.42M 4.42B 445M 174M 2.24B 174M 170M 7.42B P/E 2026 *
-3.74x
P/E 2027 * -5.86x
Enterprise Value 64.75M 46.36M 40.02M 37.49M 34.23M 64.42M 4.42B 445M 174M 2.24B 174M 170M 7.42B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 1.37x
Free-Float
58.05%
Yield 2026 *
-
Yield 2027 * -
1 day+0.98%
1 week+10.75%
Current month-11.97%
1 month-4.63%
3 months-26.43%
6 months-39.05%
Current year-47.45%
1 week 0.5
Extreme 0.505
0.53
1 month 0.46
Extreme 0.465
0.65
Current year 0.45
Extreme 0.45
1.29
1 year 0.45
Extreme 0.45
1.29
3 years 0.45
Extreme 0.45
3.15
5 years 0.45
Extreme 0.45
3.15
10 years 0.45
Extreme 0.45
3.45
Manager TitleAgeSince
Chief Executive Officer 60 2009-10-20
Director of Finance/CFO - 2024-02-25
Chief Operating Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 60 2008-06-02
Director/Board Member 65 2021-08-09
Director/Board Member - 2022-08-31
Date Insider Type Main position Quantity % Market Cap.
3/12/26 Buy

Director

21,052 0.0175%
3/12/26 Buy

Director

5,263 0.0044%
3/12/26 Buy

Director

21,052 0.0175%
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%+10.75%-48.50%-77.61% 46.13M
-1.35%-0.86%+27.46%+14.88% 233B
+0.18%+0.07%+5.40%-15.44% 152B
+1.51%-0.50%-20.92%+25.22% 130B
+0.36%-5.12%-55.76%-7.72% 67.64B
+0.29%+0.42%+11.51%+18.43% 51.85B
+0.66%-0.73%-16.25%-13.01% 50.91B
-2.44%-1.57%+29.61%+28.54% 44.46B
-1.56%+2.47%+40.75%+51.70% 41.39B
+1.94%+5.20%-14.76%+49.29% 34.01B
Average -0.16%+0.57%-4.15%+7.43% 80.48B
Weighted average by Cap. -0.49%-0.56%+3.74%+11.50%

Financials

2026 *2027 *
Net sales 37.2M 26.63M 22.99M 21.54M 19.66M 37.01M 2.54B 255M 99.82M 1.29B 99.98M 97.8M 4.26B 47.2M 33.79M 29.17M 27.33M 24.95M 46.96M 3.22B 324M 127M 1.63B 127M 124M 5.41B
Net income -17.4M -12.46M -10.75M -10.07M -9.2M -17.31M -1.19B -119M -46.69M -601M -46.76M -45.75M -1.99B -12.4M -8.88M -7.66M -7.18M -6.55M -12.34M -847M -85.15M -33.27M -428M -33.33M -32.6M -1.42B
Net Debt - -
Logo Cyclopharm Limited
Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its Technegas product is a broad-spectrum diagnostic lung imaging technology for visualization of pulmonary ventilation and lung function. It includes the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. Company distributes its products in approximately 65 countries.
Employees
104
Date Price Change Volume
26-08-28 A$0.5150 +0.98% 7,614
26-08-27 A$0.5100 -1.92% 45,681
26-08-26 A$0.5200 +1.96% 26,520
26-08-25 A$0.5100 +0.99% 6,076
26-08-24 A$0.5050 +2.02% 11,842
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3695USD
Average target price
0.7170USD
Spread / Average Target
+94.05%

Quarterly revenue - Rate of surprise